UNSPSC 51111838: Bortezomib

This classification denotes a proteasome inhibitor with the molecular formula C19H25BN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69G8BD63PP, chemically known as boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (s-(r*,s*))- but generally known as bortezomib, which bears US NIH Compound Identifier 93860. European Medicines Agency schedules Bortezomib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20020.

UNSPSC 51111838 Bortezomib is a Commodity code for a single pharmaceutical product — a proteasome inhibitor used primarily in oncology — that state and local governments procure through cooperative purchasing agreements and multi-source generic pharmaceutical contracts. State and local buyers do not typically solicit bortezomib as a line-item commodity; instead, they procure it as part of broader multi-source pharmaceutical frameworks that bundle generic drugs, branded therapeutics, and over-the-counter products into consolidated pricing agreements administered through authorized pharmaceutical wholesalers. The issuing bodies are primarily state cooperative purchasing alliances (such as MMCAP) that aggregate demand across multiple state and local facilities—including state health departments, correctional agencies, mental-health systems, and participating municipal and county healthcare operations—rather than individual counties or municipalities bidding separately. Vendors responding to these contracts must be pharmaceutical manufacturers or authorized distributors holding current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) certifications, with contractual relationships to at least two of three authorized wholesalers and chargeback-system capability.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026. The contract covers participating state and local facilities across Minnesota and Oregon, with awarded vendors effective July 1, 2026. Evaluation weights heavily price competitiveness at 75 percent, with secondary weightings on fixed pricing, administrative fee compliance, EDI capability, and regulatory agreement. Vendors must maintain insurance coverage of $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability, and comply with performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding, or class-of-trade denials. The contract carries a 3 percent administrative fee and runs two years for new responders with optional extensions at MMCAP's discretion.